Scribe Therapeutics (SCTX) vs Zura Bio (ZURA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Scribe Therapeutics is the larger company by market cap ($400.8 million vs $383.3 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | SCTX | ZURA |
|---|---|---|
| Share price | $21.17 | $4.00 |
| Market cap | $400.78M | $383.32M |
| 1-day change | +10.09% | -3.15% |
| YTD return | — | -23.66% |
| 1-year return | — | -11.31% |
| EPS (TTM) | $-3.84 | $-1.12 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $39.60 | $7.44 |
| 52-week low | $13.50 | $3.15 |
| Distance from 52-week high | -46.54% | -46.24% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +169.25% | +350.00% |
| Average volume | 358.12K | 1.44M |
| Shares outstanding | 18.93M | 95.83M |
| Employees | 82 | 40 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Scribe Therapeutics
SCTX stock →Scribe Therapeutics Inc. operates as a clinical-stage biotechnology company, focuses on research and developing genetic medicines using CRISPR-based tools to address the root cause of diseases, with a primary focus on cardiometabolic conditions in the United States.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 82 employees
About Zura Bio
ZURA stock →Zura Bio Limited, a clinical-stage biotechnology company, develops medicines for autoimmune and inflammatory disorders in the United States. The company develops Tibulizumab, a humanized IgG4 single-chain variable fragment bispecific antibody engineered to bind and neutralize both IL-17A and BAFF within a single therapeutic molecule, which is in Phase 2 clinical trial development.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 40 employees
SCTX vs ZURA FAQ
Which is bigger, Scribe Therapeutics or Zura Bio?
Scribe Therapeutics (SCTX) is larger, with a market capitalization of $400.78M compared with $383.32M for Zura Bio (ZURA).
Are Scribe Therapeutics and Zura Bio in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.